Simplifying Progress

Investors Presentation

Q1 2022 Results

Disclaimer

This presentation contains statements concerning the future performance of the Sartorius Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarantee that they will actually materialize.
This is because our assumptions harbor risks and uncertainties that could lead to actual results diverging substantially from the expected ones. It is not planned to update our forward-looking statements.

Throughout this presentation, differences may be apparent as a result of rounding during addition.

Agenda

Overview | Strategy

Bioprocess Solutions Division

Lab Products & Services Division

Q1 2022 Results | FY 2022 Guidance

SARTORIUS

Partner of biopharmaceutical research and industry

We empower scientists and engineers to simplify and accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine.

The United Nations' sustainability goal 'Good Health and Well-Being' is thus an integral part of our core business.

Sartorius at a glance

~€3.45bn
Sales revenue 2021

~22%
Sales CAGR[1] 2016-2021

34.1%
EBITDA margin[2] 2021

60+
Locations worldwide,
headquartered in Göttingen, Germany

~ 14,000
Employees

High exposure to attractive biopharma and life science industry



1 For continued operations, in constant currencies 2 Excluding extraordinary items

Strategic focus of both divisions on the biopharma value chain



Attractive market environment offers strong growth opportunities

Growing and aging population

9 billion people by 2050[1]

World population over age 60 in 2050
>2bn



World population over 60 in 2021
~1bn

Biologics are gaining importance

Share of biologics in pharma end market[2]

Sales share of biologics in 2026
~37%



Sales share of biologics in 2021
~34%

~10% CAGR
for the biopharma market
in 2021 – 2026

1 United Nations: World Population Prospects, 2019   2 Evaluate Pharma: World Preview 2021, Outlook to 2026, July 2021

Sales revenue has doubled over the last 5 years

Sales CAGR	**~+18%**
EBITDA[1] margin	**+14.4pp**



Sales, growth and CAGR 2011-21 for continued operations, in constant currencies 1 Excluding extraordinary items

SARTORIUS

Regional balance better reflecting end-markets



CAGR for continued operations

Accelerated and extended global capacity expansion

CAPEX ratio

in %



1 Incl. discontinued operation 2 Based on 2021 guidance

CAPEX composition 2022

~X%	Major projects
~3%	Regular expansion
~2%	Capitalized R&D
~3%	Maintenance

Regionalizing our supply chain and manufacturing

Expansion of membrane and filter production capacities

Expansion of bioreactor production capacities

Expansion of fluid management and cell culture media production capacities

SARTORIUS

M&A strategy – adding innovation, enhancing focus



Acquisition criteria

Portfolio: Complementary products or technologies

Market position: Either among the Top 3 or unique selling point

Integration: Management capacity; cultural fit

Price: Fair valuation; reach Sartorius' profitability level in 2-3 years

Recent acquisitions strengthen portfolio...

Acquisition of selected life science assets from Danaher

~$825m Purchase price	**~$170m** Sales revenue in 2019
+ 300 Employees	**May 2020** Date of consolidation

- Assets include bioanalytical tools for LPS; upstream and downstream technologies for BPS

Acquisition of BIA Separations

€360mn Purchase price	**~€25m** Sales revenue in 2020e
+ 120 Employees	**Nov. 2020** Date of consolidation

- Technology for purification in advanced therapy processes
- Consolidated in BPS division

SARTORIUS

...especially in downstream...

Acquisition of WaterSep BioSeparations

~$2.5m	+ 15	Dec. 2020
Sales revenue in 2020e	Employees	Date of consolidation

- Innovative hollow fiber crossflow filtration units
- Consolidated in BPS division
- Purchase price $27mn plus earn-out

Agreement to acquire chromatography process equipment division from Novasep

~€37m	+ 100
Sales revenue in 2020e	Employees

- Resin-based batch and intensified chromatography systems
- Consolidated in BPS division
- Purchase price not disclosed; regulatory approvals pending

…and cell culture media

Acquisition of CellGenix

~€20m	+ 70	Jul. 2021
Sales revenue in 2020	Employees	Date of consolidation

- Cell culture components for advanced therapies
- Consolidated in BPS division
- Transaction volume of €100m in cash for 51% stake[1]

Acquisition of Xell

~€5m	+ 35	Aug. 2021
Sales revenue in 2021e	Employees	Date of consolidation

- Media and feed supplements for cell cultures
- Consolidated in BPS division
- Purchase price of around €50m + earn-out components

1 Remaining assets to be acquired at the beginning of 2023 and 2026

Acquisition of Automated Lab Solutions expands LPS’ bioanalytics offering

Jena, Germany

~30 employees

High single-digit revenue, double-digit EBITDA margin

Closed January 2022

CellCelector

Instruments and consumables

Strategic rationale

- Complementary technology for automated analysis, selection and isolation of cells
- Improves access to life science customers in very early stages of drug development; leverage Sartorius` reach and product development capabilities

Acquisition terms

- Transaction volume of ~€24m in cash for 62.5% stake
- Remaining shares will be acquired in 2026

Ambitious climate targets to reduce CO_2 emission intensity until 2030

CO_2 emission intensity

Emissions in proportion to sales (kt CO_2 / €)



- Ambitious targets also compared to other initiatives: EU`s “Fit for 55” program: ~8.5% p.a.; Science Based Targets: ~7.0% p.a.; average commitments from Sartorius' customers and suppliers: ~8.5% p.a.; (different target formats translated into approximate intensity reduction targets)
- Gross reduction of emissions is first priority; additional compensation measures may be defined at a later point in time
- Spending an average of around one percent of sales revenue annually for corresponding measures over time
- In FY22 expenses will account for about 0.5% of consolidated group sales revenue

1 ~450 kt CO_2 emissions / ~1.8bn € sales revenues = ~250 g/€

SARTORIUS

Updated profitability targets for 2025

	BPS	LPS	Sartorius Group
Sales revenue	**~€3.8bn** unchanged	**~€1.2bn** unchanged	**€5bn** unchanged
EBITDA margin	**~36%** previously **~34%**	**~28%** previously **~25%**	**~34%** previously **~32%**



Margin targets for each division and the Group include expenses for reduction of CO_2 emission intensity of around 1% of sales.

2025 targets are based on 2020 currency exchange rates; EBITDA excluding extraordinary items

SARTORIUS

Sales revenue targets need to be considered over a multi-year period



- Projected CAGR 2019-25 well above previous periods and above initial expectations
- Extraordinary growth from 2019 to 2021 even excluding Corona effects significantly exceeds fundamental market growth
- Sartorius' 2025 revenue target is based on the assumption of no pandemic-related sales (vs. ~€500m in FY21 and 22)

SARTORIUS

Our products are widely used in the development and production of biologics against COVID-19

In **BPS** we helped our customers to manage extremely challenging development timelines and to ease scaling of vaccine processes all the way to commercialization

- Education on SUT processes
- Delivery of key products across vaccine modalities (viral vectors, mRNA, proteins) and Covid-19 therapeutics
- Joint development of solutions with our application expertise

---

Vaccine development acceleration here to stay

- mRNA validated
- New technologies in manufacturing; capacity and technology decisions established
- Pace of development

Our **LPS** solutions contribute to identifying COVID-19 infection and advancing vaccine research and development

- Patient testing
- Environmental testing
- Vaccine research
- Virology



Agenda

Overview | Strategy

Bioprocess Solutions Division

Lab Products & Services Division

Q1 2022 Results | FY 2022 Guidance

Snapshot of the Bioprocess Solutions Division

Total solution provider for biomanufacturing

Track record of dynamic growth

Sales revenue, € in millions; EBITDA margin[1] in %



Global footprint

Division sales by region

High share of recurring revenues

Division sales by category



Based on FY 2021 figures; sales CAGR in constant currencies, including non-organic growth 1 Excluding extraordinary items

Generating revenue throughout the lifecycle of a biopharma drug

	Preclinical (1 year)	Clinical (4-7 years)	Commercial (15+ years)
Stage	**Preclinical** (1 year)	**Clinical** (4-7 years)	**Commercial** (15+ years)
Scale	Process development	Proof of concept - pilot	Large

- Wide product range of equipment and consumables for all stages (from pre-commercial to large-scale manufacturing); optimal scalability
- Engineering support with excellent application knowhow and understanding of the entire bio-production process
- Production process of each individual drug is subject to validation by health authorities (e.g. FDA, EMA) and part of the drug approval

Covering most steps of the biopharmaceutical manufacturing process

- Differentiated by the range and completeness of the portfolio
- Excellent positioning in key single-use technologies
- Internationally recognized supplier enabling innovation in bioprocessing through own R&D and partnerships



Integrated services and technologies for all types of biopharmaceuticals



- ~ 95% of BPS revenue generated with bio/pharma customers
- Antibodies are most relevant; strong position in vaccines as well
- BPS provides solutions for the development and production of all biotechnologically derived drugs and cell derivatives
- These also include new modalities such as cell and gene therapies and viral vectors

The market landscape is dynamic across therapy modalities

Protein-based therapies



- mAbs
- Bi-/Multi-specifics
- Bioconjugates | ADCs
- Recombinant proteins and peptides
- Protein-based vaccines

Viral-based therapies



- Viral vectors for gene therapy
- Virus and viral vector vaccines
- Oncolytic viruses
- Novel modalities (e.g., mRNA, DNA, Exosomes)

Advanced therapies



- Cell therapy (e.g., iPSC, MSC)
- Gene-modified cell therapy (CAR-T)



Unmet needs

Efficiency	Yields	Robust manufacturing

Share of molecules in R&D pipeline; source: Global Data, March 2021

Competitive portfolio across our relevant end-markets

	Sartorius	Merck | Millipore	Danaher: Pall	Danaher: Cytiva[1]	Thermo Fisher	Top 3 Players
Filtration						1. Merck | Millipore 2. Danaher | Pall 3. Sartorius
Fluid Management						1. Sartorius 2. Thermo Fisher 3. Merck | Millipore
Fermentation						1. Sartorius 2. Thermo Fisher 3. Danaher | Cytiva
Purification						1. Danaher | Cytiva 2. Merck | Millipore 3. Sartorius
Cell Culture Media						1. Thermo Fisher 2. Merck | Millipore 3. Danaher | Cytiva



Pie charts indicate completeness of product offering

1 Formerly GE Biopharma

BIA Separations - Bioprocessing innovator, addressing bottlenecks in advanced therapies

- Ajdovščina, Slovenia
- ~120 employees
- Quadrupling production capacity till end 2021
- Acquired November 2020

Monolithic columns

Portfolio

- Pre-packed monolithic columns optimized for purification in advanced therapy processes (e.g. viruses, plasmids, exosomes)
- Provides significantly higher yield by avoiding shearing effects which occur in traditional purification processes, e.g. in chromatography

Positioning

- Monoliths already used in production of first commercialized advanced therapeutics
- Strong presence in (pre-) clinical projects

WaterSep BioSeparations – Further broadening our filtration portfolio

Marlborough, USA

~15 employees

R&D and production of membranes and cartridges

Acquired December 2020

Hollow fiber cartridges

Portfolio

- Hollow-fiber membrane devices and pre-sterilized assemblies for crossflow filtration applications in upstream and downstream
- Addresses customer needs for cost- and time-saving solutions

Stategic fit

- Complements offering for cell and gene therapy applications, cell harvesting and various solutions for intensified bioprocessing

CellGenix – Extending our cell culture media offering

Freiburg, Germany

~70 employees

GMP manufacturing and R&D laboratories

Acquired July 2021

Cytokines and growth factors

Cell culture media

Supplements and cells

Portfolio

- Critical cell culture components for advanced therapies
- Portfolio includes cytokines and growth factors, cell culture media, supplements and cells

Strategic fit

- Perfect fit with our existing media offering; combined portfolio makes us even more relevant for customers in this fast-growing segment of the biopharma market
- Freiburg to be established as a Group-wide competence center for the development and production of cell culture components

SARTORIUS

Xell – Another building block to establish a strong media business

Bielefeld, Germany

~35 employees

Major state-of-the-art capacity expansion recently completed

Acquired July 2021

Cell culture media and feed supplements

Portfolio

- Media and feed supplements for cell cultures; focus on viral vectors that are used in gene therapeutics and vaccines
- Analytical services for characterizing, screening, and quantifying media components, as well as for optimizing media composition

Strategic fit

- Expanding our current media offering by specialized media and strengthen media analytics capabilities
- Accelerating the expansion of our production network in this fast-growing area

SARTORIUS

U.S. remains most important market; China with highest growth rates

Biologics market growth forecast

SARTORIUS

The Chinese market is in the next development phase

Dynamic increase in new biopharma companies



Increasingly focusing on innovative medicines

China's activity as a percentage of global activity



Source: BCG, Sartorius

Biosimilars: Strong growth, big opportunities

- Major blockbuster biologics are going off-patent
- Time-to-market is key as only the first providers are most likely profitable
- Several approvals in Asia and Europe; U.S. at the beginning
- For now, relatively small market but with strong growth
- Single-use is the preferred platform for biosimilars

Biosimilars will outperform the biologics market

€ in billions



Growing number of biosimilar approvals

E.U. and U.S.



SARTORIUS

Pioneer and leader in the growing single-use technology market

Single-use market penetration expected to increase from ~35% to ~75%

Single-use products offer advantages over conventional stainless-steel devices

- Capex|Opex reduction over entire lifecycle
- Reduced risk of cross-contamination
- Higher flexibility; advantageous for biosimilars



Single-use allows manufacturers to mitigate investment risks

- Construction of stainless-steel based facilities takes longer and is more complex compared to single-use
- Therefore, investment in stainless-steel facilities has to start in early clinical phase II
- The construction of single-use facilities may start in clinical phase III, reducing investment risks of our clients

	Clinical Phase I	Clinical Phase II	Clinical Phase III
Probability that candidate advances to next stage	~ 60%	~ 30%	~ 50%
Probability of approval	~ 10%	~ 15 %	~ 50%

Data based on: Wong et al. (2018): Estimation of clinical trial success rates and related parameters

Analytical technologies to improve process economics and safety

- Bioprocess sensors, analyzers and software
  - Collect, monitor and control quality-critical parameters
  - Analyze data to obtain a better process understanding
  - Use knowledge for process development, optimization and automation
- Allows customers to increase time-to-market, to reduce COGS, to improve process robustness and product quality
- Intention to upgrade Umetrics software suite with advanced analytics technologies such as AI and machine learning
- Data analytics just at the beginning in biomanufacturing with high potential

High innovation dynamics in Biopharma

Development of new drugs and vaccines must be accelerated, e.g. through more automation

Increased efficiency possible in the production of 'classic' biopharmaceuticals and biosimilars

New tools and methods required e.g. for novel cell and gene therapies

Future drug manufacturing is more automated, intensified and scalable

Limited dependence on individual accounts

Long-term business relationships with leading global (bio-) pharma companies

GSK GlaxoSmithKline · Novartis · Boehringer Ingelheim · Lonza · Sanofi · Roche · Pfizer · Amgen · Bayer HealthCare Pharmaceuticals · MSD

Limited dependence on individual accounts

Sales to Top 50 customers
in 2021, € in millions



- More than half of 2021 BPS sales were generated with the Top 50 customers
- No individual customer accounts for more than 5% of BPS sales revenue

SARTORIUS

Four strong pillars drive above-average growth

	Pharma market	CAGR 3-6%
	Biopharma market	CAGR ~10%
	Single-use penetration	Double-digit growth
	Market share gains	Esp. in North America

~+21% Organic CAGR[1]



1 CAGR 2014 to 2021, excluding FX effects and acquisitions

Agenda

Overview | Strategy

Bioprocess Solutions Division

Lab Products & Services Division

Q1 2022 Results | FY 2022 Guidance

Snapshot of the Lab Products & Services Division

Premium vendor for laboratories

Global footprint

Division sales by region



Division in transition to a new growth and profitability profile

Sales revenue, € in millions; EBITDA margin[1] in %



Based on FY 2021 figures; sales growth and CAGR in constant currencies, including acquisitions 1 Excluding extraordinary items

SARTORIUS

Portfolio includes lab essentials and bioanalytical instruments; increased focus on life science end-market

Life Science Research sales
~55%

- Lab balances, pipettes, lab water systems and filtration for bio/pharma QC/QA
- ~30% share of bioanalytics; used for analysis of cells or biomolecular interactions in drug and cell line development

Applied Research sales
~45%

- Lab balances, pipettes, lab water systems and filtration
- Addresses QC/QA laboratories in food & beverage and chemical industry among others

Strong market position in essential laboratory product categories

- Average global market share of >10%
- High gross margins offer potential for economies of scale
- Growth potential especially in the U.S. and Asia
- Market growth related to R&D spending in the individual end markets

Lab balances

#2

Microb. analysis

#2

Lab filtration

#3

Pipettes

#4

SARTORIUS

Bioanalytical tools to address pain points of our customers

Drug discovery	Preclinical testing	Clinical trials	Drug approval
4-5 years	1 year	4-7 years	1-2 years



>€2bn
Average costs of developing a successful drug

~10 %
Probability of clinical success (Phase I to approval)

>10 years
From drug discovery to approval

Our approach

- Facilitate digitalization and automatization
- Decrease likelihood of failure
- Reduce time and costs in molecule development; increase speed-to-market

Based on data from the Tufts Center for the Study of Drug Development and the Association of the British Pharmaceutical Industry

SARTORIUS

Overview of bioanalytical portfolio

Solutions for cell analysis

- IncuCyte: Real-time imaging and analysis of living cells

- iQue Screener: Rapid, high content analysis of cells, beads and secreted proteins

Solutions for protein analysis

- Octet: Real-time, label-free measurement of biomolecular interactions

Competitive environment

- Beckman Coulter
- Becton Dickinson
- Bio-Rad
- Cytiva
- Merck
- PerkinElmer
- Thermo Fisher
- ...

Solutions complement each other, optimize successive workflows and have synergies with BPS products

Application example: Molecule development

iQueScreener
Screening of antibody libraries for target-reactive candidates

Octet
Measure how strong the identified antibodies bind to their target and rank


IncuCyte | iQueScreener
Selection of lead candidates and functional characterization

Application example: Cell line development

Octet
Identify high-producing clones in expression library

ambr15 (BPS division)
Culture identified clones on small-scale


Octet | iQueScreener
Analysis and characterization of cell line and antibodies

Since 2019, we have increased our overall addressable market

We now better serve **attractive and growing** customer segments with our LPS solutions:

- **Innovative technologies** for research, drug discovery, quality control and process development
- **Critical tools** for clinical, government and environmental testing and monitoring



The addition of the **Octet platform, and specialty media** has increased our market opportunity and strengthened our product offering

Overall addressable market growing in the mid- to high- single digits

Agenda

Overview | Strategy

Bioprocess Solutions Division

Lab Products & Services Division

Q1 2022 Results | FY 2022 Guidance

SARTORIUS

Strong organic growth; further margin increase

Sartorius Group in millions of € unless otherwise specified	Q1 2021	Q1 2022	▲ in %	▲ in % cc[1]
Sales revenue	791.1	**1,024.8**	+29.5	+25.4
Order intake	1,138.6	**1,112.2**	-2.3	-5.8
Underlying EBITDA[2]	263.5	**349.0**	+32.4	
Underlying EBITDA[2] margin in %	33.3	**34.1**	+0.8pp	
Underlying EPS[3] (ord.) in €	1.77	**2.44**	+37.6	
Underlying EPS[3] (pref.) in €	1.78	**2.45**	+37.3	

- Acquisitions contribute close to 2pp to sales growth
- OI is normalizing as expected; prior-year figure impacted by pandemic and changed ordering patterns by some customers
- Underlying EBITDA margin increased despite FX headwinds and higher costs for logistics and materials

1 Constant currencies 2 Underlying = excluding extraordinary items 3 Underlying EPS = based on net profit after non-controlling interest; adjusted for extraordinary items as well as amortization and based on a normalized financial result and normalized tax rate

Double-digit growth in all regions led by the Americas

Americas
€ in millions



EMEA
€ in millions



Asia|Pacific
€ in millions



Sales by Region
in %



- Americas: Dynamic growth of both divisions, especially of the LPS bioanalytics business
- EMEA: BPS with substantial growth against high comparables; LPS with robust performance
- Asia|Pacific: Very solid development of BPS; LPS with strong performance

Acc. to customers' location; growth in constant currencies

SARTORIUS

Bioprocess Solutions: High demand across the portfolio; supply chains remain strained

Order Intake
€ in millions



Sales Revenue
€ in millions



Underlying EBITDA & Margin
€ in millions



- Strong organic growth; acquisitions contribute around 2 percentage points
- OI is normalizing as expected; prior-year figure impacted by pandemic and changed ordering patterns by some customers
- Increase of underlying EBITDA margin despite FX headwinds and higher costs for logistics and materials

Lab Products & Services: Dynamic development, especially in the bioanalytics business and the U.S.

Order Intake
€ in millions



Sales Revenue
€ in millions



Underlying EBITDA & Margin
€ in millions



- Substantial growth in sales, order intake and earnings; M&A contribute around 1pp to sales growth
- Expanded profitability due to economies of scale, a favorable product mix and despite FX headwinds

Strong cash flow influenced by buildup of inventories

Sartorius Group in millions of € unless otherwise specified	Q1 2021	Q1 2022	▲ in %
Underlying EBITDA	263.5	349.0	+32.4
Extraordinary items	-5.1	-5.7	-11.8
Financial result	-20.1	71.9	n.m.
Underlying net profit[1,2]	121.7	167.2	+37.5
Reported net profit[2]	90.3	205.6	+127.7
Operating cash flow	228.9	190.2	-16.9
Investing cash flow[3]	-90.4	-162.9	-80.1
CAPEX ratio (in %)	10.2	9.4	-0.8pp

- Cash flow influenced by higher inventories to support supply security
- Financial result mainly driven by valuation effect of earn-out liability regarding BIA Separations
- Investing cash flow reflects substantial CAPEX program and M&A

Q1 2021 figures restated due to final PPA for the acquisitions of BIA Separations and WaterSep BioSeparations 1 Underlying net profit = net profit adjusted for extraordinary items, amortization and based on a normalized financial result and a normalized tax rate 2 After non-controlling interest 3 Net cash flow from investing activities and acquisitions

Robust financial indicators

Key Financial Indicators

Sartorius Group	Dec. 31, 2021	Mar. 31, 2022
Equity ratio in %	30.2	33.1
Net debt in millions of €	1,732.7	1,810.8
Net debt | underlying EBITDA[1]	1.5	1.4

Net Debt and Net Debt to Underlying EBITDA



1 Includes underlying pro forma EBITDA of acquisitions completed in 2021 and 2022

SARTORIUS

Guidance 2022 confirmed: Double-digit sales growth, sustained high profitability; uncertainties yet on a further elevated level

Guidance 2022[1]	Sales revenue growth	Underlying EBITDA margin
Sartorius Group	~15% - 19%	~34%
thereof from acquisitions	~2pp	
Bioprocess Solutions	~17% - 21%	~36%
thereof from acquisitions	~2pp	
Lab Products & Services	~6% - 10%	~26%
thereof from acquisitions	~1pp	

- Margin targets include expenses for reduction of CO_2 emission intensity of around 0.5% of sales
- CAPEX ratio expected at around 14%
- Net debt to underlying EBITDA anticipated at around 1.1

1 In constant currencies

Appendix

Corporate responsibility & further financial information

To Sartorius, sustainability means operating responsibly over the long term – with respect to business partners, employees and society as well as to natural resources. Learn more about our commitment:

- SRI Presentation
- GRI Report 2020

Please click below for further financial information:

- Earnings Release Q1 2022
- Annual Report 2021
- Earnings Release 9M 2021
- Half-Year Report H1 2021

Sartorius shares – an attractive investment

Biopharma market fueled by long-term growth drivers

Favorable market positions in key technologies and high brand awareness

Global presence with strong base in growth regions

High entry barriers, low price-sensitivity and consolidated competitive landscape

Diversified revenue base and high share of recurring revenues provide low volatility

Proven growth track record: Sales CAGR[1] of ~16% over the last five years

1 For continued operations, in constant currencies

SARTORIUS

Sartorius legal & operational structure

Sartorius Group legal setup

Sartorius AG (~68.4m shares)
Stock market listed in Germany[1]

Ordinary shares (~34.2m shares)
~55% Administered by executor
~38% Bio-Rad Laboratories
~7% Free float

Preference shares (~34.2m shares)
~72% Free float
~28% Bio-Rad Laboratories

~74%

100%

Sartorius Stedim Biotech S.A.
Stock market listed in France

91.2m shares
~74% Sartorius AG
~26% Free float

Other Sartorius subsidiaries

Bioprocess Solutions division

Lab Products & Services division

Sartorius Group operational setup

1 The ownership relates to outstanding shares and thus excludes treasury shares. Information on shareholdings and shares in free float pursuant to the disclosure requirements of Sections 33 et seq. of the German Securities Trading Act (WpHG) and the shareholders' own disclosures. The legal disclosure requirements refer only to voting shares and not to non-voting preference shares.

SARTORIUS

Share price performance



ISIN DE0007165631 (preference share)
DE0007165607 (ordinary share)

Ticker SRT3 (preference share) | SRT (ordinary share)

Number of shares 68,415,862 - thereof pref. shares: 34,189,853 (excluding ~3.3m treasury shares); ord. shares: 34,226,009 (excluding ~3.2m treasury shares)

Indices DAX 50 ESG | DAX | TecDAX | MSCI Europe CDAX | Prime All Share Index | Technology All Share Index | STOXX Europe 600

Market cap. €24.2bn (as of April 20, 2022)

SARTORIUS

A sampling of the Bioprocess Solutions' product portfolio

Filtration

Purification

Fermentation

Fluid management

A sampling of the Lab Products and Services' product portfolio

Lab balances | Lab water systems

Bioanalytics

Lab filtration | Microb. analysis

Pipettes

Executive Board of Sartorius AG

Joachim Kreuzburg, CEO

Joined Sartorius in 1999
Member of the Board since 2003

Group Strategy, Corporate Research, Human Resources, Legal & Compliance, Communications

René Fáber

Joined Sartorius in 2002
Member of the Board since 2019

Bioprocess Solutions Division

Rainer Lehmann, CFO

Joined Sartorius in 2005
Member of the Board since 2017

Finance, Information Technology, Business Processes

Gerry Mackay

Joined Sartorius in 2015
Member of the Board since 2019

Lab Products & Services Division

Financial calendar and contacts

- **July 21, 2022**
  Publication First-Half 2022 Results | Göttingen

- **October 19, 2022**
  Publication Third-Quarter 2022 Results | Göttingen

Petra Kirchhoff

Head of Corporate Communications & IR

Phone: +49.551.308.1686
E-mail: petra.kirchhoff@sartorius.com

Sartorius Corporate Administration GmbH
Otto-Brenner-Straße 20
37079 Göttingen, Germany

Scan or click here to visit our IR website.

SARTORIUS